HiveProspectStranded Biotech Asset IntelligenceResearch intelligence
Research workspace tools

Troxatyl™ (troxacitabine)

TERMINATED · PHASE2 · Leukemia, Myeloid, Acute

Unknown stopping reason

Registry source

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.